MuReva is developing a medical device to eliminate mouth ulcers, the most common, debilitating and costly side effect of cancer therapy.
Benefits to Physicians
Reduce Treatment Interruptions, Risk of Infection, and Opioid Usage
Benefits to Patients
Reduce Pain, Increase Quality of Life, Maintain Ability to Swallow and Salivary Flow
Reduce Patient Costs, Inpatient Admissions and Increase Patient Satisfaction
Reduce Overall Cost of Care, Improve Patient Outcomes and Increase Compliance to Treatment Protocols
What’s New at MuReva Phototherapy?
MuReva Phototherapy to present at Five•Ten•Thirty program during San Diego Innovation Day
As a result of being selected as a 2022 "Cool Company" by Connect, a San Diego-based organization that helps promote top technology and life sciences startups for funding, MuReva Phototherapy will be presenting at the Five·Ten·Thirty program which is a part of the...
MuReva Phototherapy Selected as One of Top Emerging Life Sciences Companies in Southern California
MuReva Phototherapy announced today that they have been selected as one of the 2022 "Cool Companies" by Connect, a San Diego-based organization that helps promote top technology and life sciences startups for funding. Cool Companies is an annual Connect program...
MuReva Phototherapy gains investment from the Angel Physicians Fund and adds Manish Bhandari, MD, E-MBA to Board of Directors
MuReva Phototherapy has announced that the Angel Physicians Fund has made an investment in the company and in conjunction with this investment, Manish Bhandari, MD, E-MBA will join the company's Board of Directors. MuReva plans to utilize this funding to continue the...
MuReva Phototherapy Awarded 1st Place at KJK New Venture Pitch contest during Cleveland Smart Business Dealmakers Conference
MuReva Phototherapy announced that the company won the KJK Venture Pitch competition that was held during the Cleveland Smart Business Dealmakers Conference held on September 2, 2020. The annual Dealmakers Conference connects hundreds of Northeast Ohio business...
MuReva Phototherapy announces initiation of clinical study in patients with head and neck cancer
MuReva Phototherapy has announced that the company has initiated a prospective, multi-center, randomized, double-blind, and placebo controlled pivotal clinical study. This study is designed to evaluate the safety and the efficacy of the MuReva Phototherapy System to...
MuReva Phototherapy completes NIH Commercialization Accelerator Program
MuReva Phototherapy has announced that the company has completed the National Institutes of Health (NIH) Commercialization Accelerator Program (CAP) which is only available for Phase II SBIR & STTR Awardees. The NIH CAP is a 9-month program run by the Larta...